Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature
Authors:
- 15 April 2022
- journal article
- review article
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 23 (4) , 469-480
Abstract
Anti-interleukin (IL)-17 agents have shown excellent therapeutic efficacy in patients with psoriasis and are expected to be expanded to other chronic inflammatory diseases. However, patients receiving anti-IL-17 agents are at an increased risk of developing Candida infection, with some agents reported to increase the incidence in a dose-dependent manner. Interleukin-17 is secreted by the Th17 subset of CD4+ lymphocytes, CD8+ T cells, and innate cells, including natural killer T cells, lymphoid tissue inducer cells, innate lymphoid cells, and γδ-T cells, and plays an important role in antifungal defense. Genetic defects in the IL-17-signaling pathway in both humans and animal models render susceptibility to candidiasis caused by Candida albicans. The purpose of this narrative review is to evaluate the literature on the role of IL-17 in protection against candidiasis, the prevalence of candidiasis in anti-IL-17 agent use, and to offer clinical recommendations on the diagnosis and management of anti-IL-17 medication-associated candidiasis.Keywords
This publication has 52 references indexed in Scilit:
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 TrialsNew England Journal of Medicine, 2014
- Oral candidiasis in patients with psoriasis: Correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatmentJournal of the American Academy of Dermatology, 2013
- Oral Candida colonization and candidiasis in patients with psoriasisOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2012
- Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for ChemotherapyMycoses, 2011
- Candida-Host Interactions in HIV DiseaseAdvances in Dental Research, 2011
- Oropharyngeal candidiasis in the era of antiretroviral therapyOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2010
- Activity of Contemporary Antifungal Agents, Including the Novel Echinocandin Anidulafungin, Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007)Journal of Clinical Microbiology, 2009
- Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasisJournal of Experimental Medicine, 2009
- Oral candidiasisPostgraduate Medical Journal, 2002
- Oral versus intra‐vaginal imidazole and triazole anti‐fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic reviewBJOG: An International Journal of Obstetrics & Gynaecology, 2002